Renal cell carcinoma (RCC) is the most
common type of kidney or renal cancer, according to the American Cancer
Society, with around 80-90% of the cancer cases reported being diagnosed
as renal cell carcinoma. Transitional cell carcinoma (TCC) is another
type of kidney cancer present among a few individuals (5% – 10% of the
kidney cancer patients in the U.S.). At times, surgical treatment alone
is not sufficient for treating RCC; if a person has developed metastatic
cancer, he/she could be recommended for additional treatment regimens.
Targeted therapies or immunotherapies are the most commonly prescribed
treatments for kidney cancer. Targeted therapies are known to act at the
cellular level, hence their accuracy and effectiveness increases with
reduced toxicity. Therefore, kidney cancer drugs are among the only
life-prolonging treatment regimens available for patients with advanced
stage metastatic tumor.
The global kidney cancer drugs market is expected to grow at a
stable growth rate during the forecast period, due to various factors
such as increasing geriatric population and rising incidence of kidney
cancer as well as approval of novel drug molecules. However, few factors
that are expected to negatively affect the growth of the market are
increasing preference for generic drug variants and high prices of
branded cancer drugs.
The global kidney cancer drugs market
has been segmented based on major branded drugs and geography. Based on
prominent brands of drugs, the kidney cancer drugs market is divided
into: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib),
Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent
(Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib). In terms
of revenue, Sutent was the largest-selling kidney cancer drug in 2013.
This is because Sutent is the most commonly prescribed drug in the
first-line treatment against kidney cancer and is among the most studied
drugs in its class for multiple indications, as it targets multiple
receptor tyrosine kinases (RTKs). In February 2006, the U.S. FDA
approved Sunitinib for two indications, namely, RCC and gastrointestinal
stromal tumor (GIST), making it the first cancer drug to receive
approval in the U.S. However, GSK’s Votrient is expected become the
market leader by 2017 surpassing Sutent and other competitors due to low
pricing and superior first-line penetration, displaying the fastest
growth rate at CAGR of over 40% from 2012 to 2016 and over 5% from 2016
to 2020. The market growth of Votrient is supported by the fact that
during Phase III comparison trials, the drug showed better patient
compatibility and safety profile with lower side effects as compared
with interferon, placebo and other targeted therapies.
Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537
North America is the largest market for kidney cancer drugs due the
commercial availability of major branded drugs for kidney cancer
treatment and presence of large patient pool suffering from various
forms of kidney cancer. North America dominated the market mainly due to
the presence of a large patient population and the lucrative health
care system tailor-made for the pharmaceutical industry. Exclusive
patent rights and presence of a large health care insurance base have
driven the pharmaceutical market in the U.S., thereby making North
America the market leader for kidney cancer drugs. Asia Pacific is
expected to observe an admirable growth due to multiple factors such as
rising incidence of renal cell carcinoma, growing geriatric population
and rapid economic development in nations such as India, China,
Singapore, Malaysia and others, that contribute to the growth of kidney
cancer drugs market in the region.
At present, the market is highly consolidated and aggressive in
nature due to the presence of biggest pharmaceutical giants such as
Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG
and Pfizer, Inc. Among these, Pfizer, Inc. grabbed the largest share of
the global kidney cancer drugs market in 2013. Since, Sutent (Sunitinib)
and Inlyta (Axitinib) are the leading drugs for the treatment of kidney
cancer, the global market of kidney cancer drugs is ruled by one of the
world’s largest biopharmaceutical companies, Pfizer, Inc. However,
other established market players such as Novartis and GSK are focusing
on expanding their geographical presence as well as distribution network
in emerging nations, since Asia Pacific, Latin America and the Middle
East are developing regions with an increasing incidence rate of various
forms of kidney cancer and improving economic conditions.
No comments:
Post a Comment